In France, over two million people live with a chronic wound - and wait on average more than 220 days to heal. A severe, costly medical reality that is still too often accepted as inevitable. Luxoderm is developing WoundLight, a patented, portable, and non-invasive medical device, which accelerates healing by promoting the transition from the inflammatory phase to the proliferation phase. Fast, contactless, and easy to use, it significantly improves patients' quality of life, reduces hospitalizations, and lowers treatment costs - for healthcare professionals and the healthcare system as a whole.
The next step
Luxoderm is about to achieve two decisive milestones: validating WoundLight's efficacy thanks to the preclinical results in vivo on murine models, and securing the necessary funding to launch the pre-industrialization phase in preparation for a clinical study. These are essential steps on the path to a certified and widely deployable medical device.
Why 21st by CentraleSupélec?
In the MedTech world, convincing the right stakeholders at the right time is often as crucial as the technology itself. 21st by CentraleSupélec supports Luxoderm on three fronts: a connection to the deep tech ecosystem, in-depth work on the pitch deck and the business plan, and targeted introductions to investors - so that science can be transformed into a business.
Focus on the co-founders
Anthony Donabedian, Louis Dorlencourt
#MedTech #WoundCare #DeepTech #Innovation #Photonics
.avif)
